Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China
SAGA Metals Announces Closing of Fully Subscribed Non-Brokered Private Placement and Provides Corporate Update
